aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Bridge Medicines LLC is a biotechnology company dedicated to developing innovative drugs to combat diseases such as tuberculosis and orphan diseases. The company focuses on transforming breakthrough research into practical treatments, serving customers primarily in the United States. Their mission is to address unmet medical needs by bringing forward transformational ideas from cutting-edge scientific research.
Bridge Medicines has achieved significant milestones, including entering an exclusive license agreement with Cornell University for the UBR5 inhibitor program aimed at treating resistant cancers. The company has also expanded its pipeline with small molecule inhibitors of activated Factor XII. These advancements are supported by additional funding from inside investors, underscoring the company's impact and potential in the biotech industry.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Drug Development
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Bridge Medicines founded?
Bridge Medicines was founded in 2016.
Where is Bridge Medicines's headquarters located?
Bridge Medicines's headquarters is located in New York City, NY, US.
When was Bridge Medicines's last funding round?
Bridge Medicines's most recent funding round was for $10M (USD) in November 2020.
How many employees does Bridge Medicines have?
Bridge Medicines has 11 employees as of Feb 4, 2024.
How much has Bridge Medicines raised to-date?
As of July 05, 2023, Bridge Medicines has raised a total of $10M (USD) since Nov 13, 2020.
Add Comparison
Total Raised to Date
$10M
USD
Last Update Nov 13, 2020
Last Deal Details
$10M
USD
Nov 13, 2020
Series Unknown
Total Employees Over Time
11
As of Feb 2024
Bridge Medicines Address
780 Third Ave
New York City,
New York
10017
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts